Frontlight ResearchEarly access
Metastatic breast cancer trials in China
224 trials · From ClinicalTrials.gov, checked 17 November 2026. Ask the study team whether a trial fits you.
- Phase 1/2Taking peopleStudy of TYK-00540 Tablets in Patients With Advanced Solid Tumors
- Where
- Shanghai
- Age
- 18 years and over
- People
- 180
- Run by
- TYK Medicines, Inc
See details and how to joinNCT06950086 - Phase 3Taking peopleA Phase Ⅲ Study of Hemay022 in Combination With AI In Advanced Breast Cancer
- Where
- Beijing
- Age
- 18 years and over
- People
- 339
- Run by
- Tianjin Hemay Pharmaceutical Co., Ltd
See details and how to joinNCT06313983 - No phaseNot yet taking people in ChinaThe Efficacy of Oral Cryotherapy in Preventing TROP2-ADC-Induced Oral Mucositis in Patients With Advanced Breast Cancer
- Where
- Zhengzhou
- Age
- 18 years and over
- People
- 124
- Run by
- Henan Cancer Hospital
See details and how to joinNCT06934733 - Phase 3Not yet taking people in ChinaSirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitors
- Where
- Shijiazhuang
- Age
- 18 years and over
- People
- 312
- Run by
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
See details and how to joinNCT06929325 - Phase 1Taking peopleBortezomib Plus Cisplatin in Recurrent or Metastatic Breast Cancer
- Where
- Guangzhou
- Age
- 18 years and over
- People
- 20
- Run by
- Sun Yat-sen University
See details and how to joinNCT06900647 - Phase 3Taking peopleJSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer
- Where
- Shanghai
- Age
- 18 years and over
- People
- 228
- Run by
- Shanghai JMT-Bio Inc.
See details and how to joinNCT06846437 - Phase 1/2Enrolling by invitationRadiotherapy with Immunotherapy and Anti-Angiogenic Therapy for Advanced HER2-Negative Breast Cancer: a Single-Arm Study
- Where
- Wuhan
- Age
- 18 years to 75 years
- People
- 25
- Run by
- Zhongnan Hospital
See details and how to joinNCT06890871 - No phaseTaking people21-gene in Elder Breast Cancer Patients With Lymph Node Metastasis
- Where
- Jinan
- Age
- 65 years and over
- People
- 35
- Run by
- Qilu Hospital of Shandong University
See details and how to joinNCT06891651 - No phaseTaking peopleA Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer
- Where
- Shanghai
- Age
- 18 years and over
- People
- 36
- Run by
- Fudan University
See details and how to joinNCT06856200 - Phase 2Taking peopleEfficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer
- Where
- Beijing
- Age
- 18 years and over
- People
- 40
- Run by
- RemeGen Co., Ltd.
See details and how to joinNCT06642545 - Phase 1/2Taking peopleStudy of SHR-A1811 Combined With Pyrotinib and Bevacizumab in Advanced Breast Cancer With Brain Metastasis
- Where
- Shanghai
- Age
- 18 years and over
- People
- 74
- Run by
- Fudan University
See details and how to joinNCT06718933 - No phaseNot yet taking people in ChinaReal-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Triple-negative Breast Cancer
- Where
- Shanghai
- Age
- 18 years and over
- People
- 300
- Run by
- Fudan University
See details and how to joinNCT06798506 - Phase 2Not yet taking people in ChinaHeterogeneity of 68Ga-FAPI Uptake As Imaging Biomarker in T-DXd Treatment for Brain Metastasis of HER2 Positive Breast Cancer
- Where
- Shanghai
- Age
- 18 years and over
- People
- 50
- Run by
- Fudan University
See details and how to joinNCT06797622 - Phase 1Taking peopleThe Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase I Clinical Study
- Where
- Nanjing
- Age
- 18 years to 75 years
- People
- 200
- Run by
- The First Affiliated Hospital with Nanjing Medical University
See details and how to joinNCT06770296 - No phaseTaking peopleDrug Sensitivity of Hydrothorax and Ascite Organoids from Breast Cancer
- Where
- Hangzhou
- Age
- 18 years to 70 years
- People
- 90
- Run by
- Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT06658080 - Phase 2Not yet taking people in ChinaChidamide Combined With Angiogenesis Inhibitors and Fulvestrant for Advanced HR-positive, HER2-negative Breast Cancer
- Where
- Shantou
- Age
- 18 years to 75 years
- People
- 48
- Run by
- Jundong Wu
See details and how to joinNCT06750848 - No phaseTaking peopleAnlotinib-based Combination Therapy in Patients with Hormone Receptor-positive(HR+) Metastatic Breast Cancer(MBC) .
- Where
- Changsha
- Age
- 18 years to 75 years
- People
- 80
- Run by
- Hunan Cancer Hospital
See details and how to joinNCT06734533 - Phase 2Not yet taking people in ChinaJAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC
- Where
- Shanghai
- Age
- 18 years to 70 years
- People
- 40
- Run by
- Fudan University
See details and how to joinNCT06731153 - Phase 2Taking peopleOrganoid-based Functional Precision Therapy for Advanced Breast Cancer
- Where
- Guangzhou
- Age
- 18 years to 80 years
- People
- 252
- Run by
- Guangdong Provincial People's Hospital
See details and how to joinNCT06102824 - Phase 2Taking peopleThe Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
- Where
- Bozhou, Changde, Chuzhou, Hangzhou, Harbin, Hefei, Ma’anshan, Shanghai, Suzhou, Ürümqi, Wenzhou, Wuhan, Wuhu, Xi’an, Zhengzhou
- Age
- 18 years to 75 years
- People
- 42
- Run by
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
See details and how to joinNCT06452706 - Phase 1/2Taking peopleTIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer
- Where
- Beijing
- Age
- 16 years to 90 years
- People
- 85
- Run by
- Essen Biotech
See details and how to joinNCT06532812 - Phase 4Taking peopleThe Efficacy and Safety of Different Combination Regimens of Inetetamab in First-line Treatment of HER2 Positive Metastatic Breast Cancer
- Where
- Shanwei
- Age
- 18 years to 70 years
- People
- 200
- Run by
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
See details and how to joinNCT06641544 - Phase 2Taking peopleSNF Platform Study of HR+/ HER2-advanced Breast Cancer
- Where
- Shanghai
- Age
- 18 years and over
- People
- 620
- Run by
- Fudan University
See details and how to joinNCT05594095 - Phase 1Taking peopleAnlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 42
- Run by
- Fudan University
See details and how to joinNCT06331169 - Phase 2Taking peopleCombination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase Ⅱ Clinical Trial
- Where
- Zhengzhou
- Age
- 18 years and over
- People
- 240
- Run by
- Henan Cancer Hospital
See details and how to joinNCT06176534